Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Lung Cancer

  Free Subscription


1 Ann Oncol
1 Ann Surg
2 Ann Surg Oncol
1 Arch Bronconeumol
2 BMC Cancer
1 Cancer Cell
2 Cancer Lett
1 Cancer Res
1 Chest
1 Clin Cancer Res
4 Clin Lung Cancer
1 Clin Nucl Med
1 Eur J Cancer
1 Eur J Cardiothorac Surg
3 Int J Cancer
2 Int J Oncol
8 Int J Radiat Oncol Biol Phys
3 J Thorac Cardiovasc Surg
1 J Thorac Oncol
1 Lancet Oncol
6 Lung Cancer
1 Oncogene
5 PLoS One
2 Thorax

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Oncol

  1. PEYRAUD F, Guegan JP, Bodet D, Nafia I, et al
    Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
    Ann Oncol. 2022;33:1041-1051.
    PubMed         Abstract available

    Ann Surg

  2. HEIDEN BT, Eaton DB Jr, Brandt WS, Chang SH, et al
    Development and Validation of the VA Lung Cancer Mortality (VALCAN-M) Score for 90-day Mortality Following Surgical Treatment of Clinical Stage I Lung Cancer.
    Ann Surg. 2022 Oct 17. pii: 00000658-990000000-00288.
    PubMed         Abstract available

    Ann Surg Oncol

  3. LI D, Deng C, Fu F, Bai J, et al
    ASO Visual Abstract: Impact of Prior Cancer History on Outcomes of Resected Lung Cancer.
    Ann Surg Oncol. 2022 Oct 20. pii: 10.1245/s10434-022-12658.

  4. BONNER SN, He C, Clark M, Adams K, et al
    ASO Visual Abstract: Understanding Racial Differences in Lung Cancer Surgery Through a Statewide Quality Collaborative.
    Ann Surg Oncol. 2022 Oct 16. pii: 10.1245/s10434-022-12546.

    Arch Bronconeumol

  5. RABOSO-MORENO B, de la Vina JI, Gato-Diaz P, Jimenez-Fernandez M, et al
    NADIM II Study: What is the Ideal Time for Surgery in Stage IIIA Lung Cancer?
    Arch Bronconeumol. 2022 Sep 27. pii: S0300-2896(22)00574.

    BMC Cancer

  6. KOJIMA K, Imai S, Samejima H, Fujiwara A, et al
    PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: a retrospective cohort study.
    BMC Cancer. 2022;22:1066.
    PubMed         Abstract available

  7. LIAO K, Wang T, Coomber-Moore J, Wong DC, et al
    Prognostic value of patient-reported outcome measures (PROMs) in adults with non-small cell Lung Cancer: a scoping review.
    BMC Cancer. 2022;22:1076.
    PubMed         Abstract available

    Cancer Cell

  8. LAU SCM, Pan Y, Velcheti V, Wong KK, et al
    Squamous cell lung cancer: Current landscape and future therapeutic options.
    Cancer Cell. 2022 Oct 14. pii: S1535-6108(22)00480.
    PubMed         Abstract available

    Cancer Lett

  9. WANG Y, Wang Y, Yu J, Meng X, et al
    The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues.
    Cancer Lett. 2022 Oct 17:215947. doi: 10.1016/j.canlet.2022.215947.
    PubMed         Abstract available

  10. MYACHEVA K, Walsh A, Riester M, Pelos G, et al
    CRISPRi screening identifies CASP8AP2 as an essential viability factor in lung cancer controlling tumor cell death via the AP-1 pathway.
    Cancer Lett. 2022 Oct 14:215958. doi: 10.1016/j.canlet.2022.215958.
    PubMed         Abstract available

    Cancer Res

  11. LI M, Mok K, Mok T
    A Detouring Experience Not Recommended: Lessons Learned from PF00299804.
    Cancer Res. 2022;82:3662-3664.
    PubMed         Abstract available


  12. KORT S, Brusse-Keizer M, Schouwink DH, Citgez E, et al
    Diagnosing non-small cell lung cancer by exhaled-breath profiling using an electronic nose: a multicentre validation study.
    Chest. 2022 Oct 12. pii: S0012-3692(22)03914-9. doi: 10.1016/j.chest.2022.
    PubMed         Abstract available

    Clin Cancer Res

  13. BRAMAN N, Prasanna P, Bera K, Alilou M, et al
    Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers.
    Clin Cancer Res. 2022;28:4410-4424.
    PubMed         Abstract available

    Clin Lung Cancer

  14. SCHMID S, Cheng S, Chotai S, Garcia M, et al
    Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Sep 24. pii: S1525-7304(22)00209.
    PubMed         Abstract available

  15. KUANG Y, Singh R, Nevo A, Deitz AC, et al
    Incidence of Pneumonitis Among Limited Stage Small Cell Lung Cancer Patients Exposed to Concurrent Chemoradiation: A Systematic Literature Review and Meta-Analysis.
    Clin Lung Cancer. 2022 Sep 26. pii: S1525-7304(22)00204.
    PubMed         Abstract available

  16. PEVNER JL, Tanvetyanon T
    Targeted therapy for lung cancer with paraneoplastic disseminated intravascular coagulation: A case report and pooled analysis.
    Clin Lung Cancer. 2022 Sep 25. pii: S1525-7304(22)00206.

  17. GONUGUNTA AS, Von Itzstein MS, Hsiehchen D, Le T, et al
    Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era.
    Clin Lung Cancer. 2022 Sep 24. pii: S1525-7304(22)00208.
    PubMed         Abstract available

    Clin Nucl Med

  18. KESIM S, Oksuzoglu K, Ozguven S
    Nocardia Infection With Adrenal Gland Abscess Mimicking Metastatic Lung Cancer on FDG PET/CT.
    Clin Nucl Med. 2022 Oct 17. pii: 00003072-990000000-00310.
    PubMed         Abstract available

    Eur J Cancer

  19. MOROSI C, Bergamaschi L, Livellara V, Hassan V, et al
    Relapsing pediatric non-rhabdomyosarcoma soft tissue sarcomas: The impact of routine imaging surveillance on early detection and post-relapse survival.
    Eur J Cancer. 2022;175:274-281.
    PubMed         Abstract available

    Eur J Cardiothorac Surg

  20. YASUURA Y, Terada Y, Mizuno K, Kayata H, et al
    Quantitative severity of emphysema is related to the prognostic outcome of early-stage lung cancer.
    Eur J Cardiothorac Surg. 2022 Oct 20. pii: 6764596. doi: 10.1093.
    PubMed         Abstract available

    Int J Cancer

  21. AKHOUNDOVA D, Hussung S, Sivakumar S, Topfer A, et al
    ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.
    Int J Cancer. 2022 Aug 22. doi: 10.1002/ijc.34257.
    PubMed         Abstract available

  22. YU F, Peng M, Bai J, Zhu X, et al
    Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK/RAS pathway in ground-glass opacity pulmonary nodules.
    Int J Cancer. 2022;151:2020-2030.
    PubMed         Abstract available

  23. DWYER-NIELD LD, McArthur DG, Hudish TM, Hudish LI, et al
    PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model.
    Int J Cancer. 2022;151:2195-2205.
    PubMed         Abstract available

    Int J Oncol

  24. CAO H, Wang Z, Wang Y, Ye L, et al
    PPP1R14D promotes the proliferation, migration and invasion of lung adenocarcinoma via the PKCalpha/BRAF/MEK/ERK signaling pathway.
    Int J Oncol. 2022;61.
    PubMed         Abstract available

  25. ORTEGA MA, Navarro F, Pekarek L, Fraile-Martinez O, et al
    Exploring histopathological and serum biomarkers in lung adenocarcinoma: Clinical applications and translational opportunities (Review).
    Int J Oncol. 2022;61.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  26. TRAN PT, Sutera P, Phillips RM, Deek MP, et al
    From Idea to Clinical Practice: A Brief History of Oligometastatic Disease.
    Int J Radiat Oncol Biol Phys. 2022;114:576-580.

  27. OLADERU OT, Yerramilli D
    Aggressive Local Control of Oligorecurrence After Oligometastasis: A Tale of Competing Risk Management.
    Int J Radiat Oncol Biol Phys. 2022;114:573-574.

  28. GOODMAN CR, Strauss JB
    One Way or Another: An Oligorecurrence After an Oligometastasis of an Estrogen Receptor-Positive Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2022;114:571-572.

  29. NAVARRIA P, Baldaccini D, Clerici E, Marini B, et al
    Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study.
    Int J Radiat Oncol Biol Phys. 2022;114:762-770.
    PubMed         Abstract available

  30. KORPICS MC, Katipally RR, Partouche J, Cutright D, et al
    Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy.
    Int J Radiat Oncol Biol Phys. 2022;114:645-654.
    PubMed         Abstract available

  31. NEVENS D, Jongen A, Kindts I, Billiet C, et al
    Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
    Int J Radiat Oncol Biol Phys. 2022;114:587-595.
    PubMed         Abstract available

  32. GUTKIN PM, von Eyben R, Chin A, Donaldson SS, et al
    Local Control Outcomes Using Stereotactic Body Radiation Therapy or Surgical Resection for Metastatic Sarcoma.
    Int J Radiat Oncol Biol Phys. 2022;114:771-779.
    PubMed         Abstract available

  33. MAHMOOD U, Huynh MA, Killoran JH, Qian JM, et al
    Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade.
    Int J Radiat Oncol Biol Phys. 2022;114:666-675.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

  34. TSUTANI Y, Ito M, Shimada Y, Ito H, et al
    The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;164:1306-1315.
    PubMed         Abstract available

    Commentary: "Can we" versus "should we": The defining dilemma of mesothelioma surgery.
    J Thorac Cardiovasc Surg. 2022;164:1349-1350.

  36. LAPIDOT M, Mazzola E, Bueno R
    Outcomes of pleurectomy decortication in patients with biphasic mesothelioma.
    J Thorac Cardiovasc Surg. 2022;164:1340-1348.
    PubMed         Abstract available

    J Thorac Oncol

  37. WANG Q, Gumus ZH, Colarossi C, Memeo L, et al
    Small Cell Lung Cancer: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening and Early Detection.
    J Thorac Oncol. 2022 Oct 12. pii: S1556-0864(22)01851.
    PubMed         Abstract available

    Lancet Oncol

  38. QIN N, Wang C, Chen C, Yang L, et al
    Association of the interaction between mosaic chromosomal alterations and polygenic risk score with the risk of lung cancer: an array-based case-control association and prospective cohort study.
    Lancet Oncol. 2022 Oct 17. pii: S1470-2045(22)00600.
    PubMed         Abstract available

    Lung Cancer

  39. KAUMANNS A, Konig D, Hojski A, Cattaneo M, et al
    Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study.
    Lung Cancer. 2022;173:14-20.
    PubMed         Abstract available

  40. WANG M, Huang H, Xu Z, Li Z, et al
    Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
    Lung Cancer. 2022;173:28-34.
    PubMed         Abstract available

  41. DISSELHORST MJ, Lubeck Y, van der Noort V, Quispel-Janssen J, et al
    Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
    Lung Cancer. 2022;173:49-52.
    PubMed         Abstract available

  42. SOOSMAN SK, Schenker MP, Mazzola E, Voligny E, et al
    Safety of image guided research biopsies in patients with thoracic malignancies.
    Lung Cancer. 2022;173:53-57.
    PubMed         Abstract available

  43. SANCHIS-BORJA M, Fallet V, Fabre E, Wislez M, et al
    Characterization of lung cancers in patients with BRCA germline variants: A multicenter series.
    Lung Cancer. 2022;173:67-70.
    PubMed         Abstract available

  44. AGUADO DE LA ROSA C, Cruz Castellanos P, Lazaro-Quintela M, Domine M, et al
    Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).
    Lung Cancer. 2022;173:83-93.
    PubMed         Abstract available


  45. SEMBA S, Trapasso F, Fabbri M, McCorkell KA, et al
    Correction to: Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential.
    Oncogene. 2022 Oct 20. pii: 10.1038/s41388-022-02472.

    PLoS One

  46. NEMLANDER E, Rosenblad A, Abedi E, Ekman S, et al
    Lung cancer prediction using machine learning on data from a symptom e-questionnaire for never smokers, formers smokers and current smokers.
    PLoS One. 2022;17:e0276703.
    PubMed         Abstract available

  47. CHOW YP, Zainul Abidin N, Kow KS, Tho LM, et al
    Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
    PLoS One. 2022;17:e0276161.
    PubMed         Abstract available

  48. WU L, Zhuang J, Chen W, Tang Y, et al
    Data augmentation based on multiple oversampling fusion for medical image segmentation.
    PLoS One. 2022;17:e0274522.
    PubMed         Abstract available

  49. JIMENEZ-RAMIREZ C, Gilbert Weber D, Aguilar-Madrid G, Brik A, et al
    Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.
    PLoS One. 2022;17:e0275936.
    PubMed         Abstract available

  50. KLEINSCHMIDT SE, Andres KL, Holen BM, Buehrer BD, et al
    Mortality among mine and mill workers exposed to respirable crystalline silica.
    PLoS One. 2022;17:e0274103.
    PubMed         Abstract available


  51. ROSE JA, Hunninghake GM
    Time to move out of the shadows: ILA in patients with lung cancer.
    Thorax. 2022 Oct 21. pii: thorax-2022-219498. doi: 10.1136/thorax-2022-219498.

  52. TANAKA H, Kabata H, Emoto K, Hayashi S, et al
    Young woman with multiple lung nodules: a pulmonary oxymoron.
    Thorax. 2022;77:1155-1157.

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.